Souto GR, Pereira TSF, Castro AF, Mesquita RA. Diffuse large B-cell
lymphoma, not otherwise specified of the palate: a case report. J Clin Exp
Dent. 2013;5(5):e287-90.
doi:10.4317/jced.51127
References
1.
Fisher RI, Miller TP, O'Connor OA. Diffuse aggressive lymphoma. Hematology Am
Soc Hematol Educ Program. 2004:221-36.
http://dx.doi.org/10.1182/asheducation-2004.1.221
PMid:15561685
2.
Kemp S, Gallagher G, Kabani S, Noonan V, O'Hara C. Oral non-Hodgkin's lymphoma:
review of the literature and World Health Organization classification with
reference to 40 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod.
2008;105:194-201.
http://dx.doi.org/10.1016/j.tripleo.2007.02.019
PMid:17604660
3.
Kolokotronis A, Konstantinou N, Christakis I, Papadimitriou P, Matiakis A,
Zaraboukas T, et al. Localized B-cell non-Hodgkin's lymphoma of oral cavity and
maxillofacial region: a clinical study. Oral Surg Oral Med Oral Pathol Oral
Radiol Endod. 2005;99:303-10.
http://dx.doi.org/10.1016/j.tripleo.2004.03.028
PMid:15716836
4.
Sato Y, Onishi N, Morito T, Takata K, Mizobuchi K, Nagatsuka H, et al. Patients
with localized primary non-tonsillar oral diffuse large B-cell lymphoma exhibit
favorable prognosis despite a non-germinal center B-cell-like phenotype. Cancer
Sci. 2009;100:42-6.
http://dx.doi.org/10.1111/j.1349-7006.2008.00995.x
PMid:19018759
5.
Flowers CR, Sinha R, Vose JM. Improving outcomes for patients with diffuse
large B-cell lymphoma. CA Cancer J Clin. 2010;60:393-408.
PMid:21030533
6.
Hunt KE, Reichard KK. Diffuse large B-cell lymphoma. Arch Pathol Lab Med.
2008;132:118-24.
PMid:18181663
7.
Van der Waal RI, Huijgens PC, van der Valk P, van der Waal I. Characteristics
of 40 primary extranodal non-Hodgkin lymphomas of the oral cavity in
perspective of the new WHO classification and the International Prognostic
Index. Int J Oral Maxillofac Surg. 2005;34:391-5.
http://dx.doi.org/10.1016/j.ijom.2004.08.009
PMid:16053848
8.
Swerdlow SH, Campo S, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO
classification of tumous of haematopoietic and lymphoid tissue 4th ed. Press I,
editor. Lyon, France.2008.
9.
Abramson JS, Shipp MA. Advances in the biology and therapy of diffuse large
B-cell lymphoma: moving toward a molecularly targeted approach. Blood.
2005;106:1164-74.
http://dx.doi.org/10.1182/blood-2005-02-0687
PMid:15855278
10.
Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical
practice and translational research. Hematology Am Soc Hematol Educ Program.
2009:523-31.
http://dx.doi.org/10.1182/asheducation-2009.1.523
PMid:20008237
11.
Oyama T, Ichimura K, Suzuki R, Suzumiya J, Ohshima K, Yatabe Y, et al. Senile
EBV+ B-cell lymphoproliferative disorders: a clinicopathologic study of 22
patients. Am J Surg Pathol. 2003;27:16-26.
http://dx.doi.org/10.1097/00000478-200301000-00003
PMid:12502924
12.
Oyama T, Yamamoto K, Asano N, Oshiro A, Suzuki R, Kagami Y, et al. Age-related
EBV-associated B-cell lymphoproliferative disorders constitute a distinct
clinicopathologic group: a study of 96 patients. Clin Cancer Res.
2007;13:5124-32.
http://dx.doi.org/10.1158/1078-0432.CCR-06-2823
PMid:17785567
13.
Gutierrez A, Mestre F, Perez-Manga G, Rodriguez J. Diffuse large B-cell
lymphoma in the older. Crit Rev Oncol Hematol. 2011;78:59-72.
http://dx.doi.org/10.1016/j.critrevonc.2010.02.009
PMid:20303778
14.
Shimoyama Y, Asano N, Kojima M, Morishima S, Yamamoto K, Oyama T, et al.
Age-related EBV-associated B-cell lymphoproliferative disorders: diagnostic
approach to a newly recognized clinicopathological entity. Pathol Int.
2009;59:835-43.
http://dx.doi.org/10.1111/j.1440-1827.2009.02466.x
PMid:20021607
15.
Coiffier B. Rituximab therapy in malignant lymphoma. Oncogene. 2007;26:3603-13.
http://dx.doi.org/10.1038/sj.onc.1210376
PMid:17530014
16.
Berglund M, Thunberg U, Amini RM, Book M, Roos G, Erlanson M, et al. Evaluation
of immunophenotype in diffuse large B-cell lymphoma and its impact on
prognosis. Mod Pathol. 2005;18:1113-20.
http://dx.doi.org/10.1038/modpathol.3800396
PMid:15920553
17.
Colomo L, Lopez-Guillermo A, Perales M, Rives S, Martinez A, Bosch F, et al.
Clinical impact of the differentiation profile assessed by immunophenotyping in
patients with diffuse large B-cell lymphoma. Blood. 2003;101:78-84.
http://dx.doi.org/10.1182/blood-2002-04-1286
PMid:12393466
18.
Yamaguchi M, Seto M, Okamoto M, Ichinohasama R, Nakamura N, Yoshino T, et al.
De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109
patients. Blood. 2002;99:815-21.
http://dx.doi.org/10.1182/blood.V99.3.815
PMid:11806981
19.
Veelken H, Vik Dannheim S, Schulte Moenting J, Martens UM, Finke J,
Schmitt-Graeff A. Immunophenotype as prognostic factor for diffuse large B-cell
lymphoma in patients undergoing clinical risk-adapted therapy. Ann Oncol.
2007;18:931-9.
http://dx.doi.org/10.1093/annonc/mdm012
PMid:17395602
20.
Chang CC, McClintock S, Cleveland RP, Trzpuc T, Vesole DH, Logan B,
Kajdacsy-Balla A, Perkins SL. Immunohistochemical expression patterns of
germinal center and activation B-cell markers correlate with prognosis in
diffuse large B-cell lymphoma. Am J Surg Pathol. 2004;28:464-70.
http://dx.doi.org/10.1097/00000478-200404000-00005
PMid:15087665
21.
Bhattacharyya I, Chehal HK, Cohen DM, Al-Quran SZ. Primary diffuse large B-cell
lymphoma of the oral cavity: germinal center classification. Head Neck Pathol.
2010;4:181-91.
http://dx.doi.org/10.1007/s12105-010-0184-4
PMid:20533006
PMCid:PMC2923304
22.
Gomez H, Hidalgo M, Casanova L, Colomer R, Pen DL, Otero J, et al. Risk factors
for treatment-related death in elderly patients with aggressive non-Hodgkin's
lymphoma: results of a multivariate analysis. J Clin Oncol. 1998;16:2065-9.
PMid:9626205
23.
Vose JM, Armitage JO, Weisenburger DD, Bierman PJ, Sorensen S, Hutchins M, et
al. The importance of age in survival of patients treated with chemotherapy for
aggressive non-Hodgkin's lymphoma. J Clin Oncol. 1988;6:1838-44.
PMid:2462026
24.
Armitage JO. How I treat patients with diffuse large B-cell lymphoma. Blood.
2007;110:29-36.
http://dx.doi.org/10.1182/blood-2007-01-041871
PMid:17360935